Skip to main content

Royalty Pharma

Royalty Pharma plc is an American biopharmaceutical buyer and funder of intellectual property royalties based in the life sciences industry. The company operates by acquiring revenue-producing royalties on approved biopharmaceutical products and funding late-stage clinical research trials. Its portfolio of royalty assets includes rights to commercial blockbuster therapies such as Trikafta, Imbruvica, Tysabri, Tremfya, and Spinraza. Principal revenue drivers consist of recurring royalty cash flows generated from the global commercial sales of underlying pharmaceutical products marketed by major drug companies. Royalty Pharma serves global healthcare end markets by providing capital to academic institutions, biotechnology startups, and research hospitals. The enterprise holds a dominant market position as the largest buyer of biopharmaceutical royalties and a premier provider of non-dilutive capital to the life sciences sector. Headquartered in New York City, New York, the company's Class A common stock is listed on the Nasdaq Stock Market under the ticker symbol RPRX.

86 of the funds FundTelligence covers report a position in Royalty Pharma.

Legal name
Royalty Pharma Plc
Sector
Health Care
Country
United States
Funds holding it
86

Funds holding Royalty Pharma

Showing the 8 largest of 86 funds holding it.

Loading...